How have the shares performed?
Genetic Technologies Limited (GENE) saw an uptrend of 9.13% in the recent trading with $4.54 being its most recent. The current price level -55.92% lower than the highest price of $10.30 marked by the stock while trading over the past 52-weeks, whereas it is 130.46% higher than the lowest price of $1.97 the company dropped to over past 52-weeks. The latest news story on GENE appeared in GlobeNewswire under the title “US Patent Office Grants Foundational Pharmacogenomic Patent” on Jun-11-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -12.36% below one month high and is +28.98% above of the lowest during that time. Looking into the simple moving average, Genetic Technologies Limited (GENE)’s stock stands at a SMA-50 of $4.00 while that of 5-day is reading $4.14.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and GENE’s SMA-200 as of now is $3.91.
Genetic Technologies Limited Earnings – What Happened With GENE
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. During the reported three-month period, company’s sales were $16.4 million.
GENE – Genetic Technologies Limited Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 13.64 million. GENE does have institutional investors; and they hold 2.70% of the stock.
Genetic Technologies Limited – Insider Activity and Holdings
As on Mar 30, 2021, Citadel Advisors LLC was the top most holder in Genetic Technologies Limited (NASDAQ:GENE) with an ownership of 0.1 million shares of the company or 0.70% of the stake worth $0.44 million. The filing also reveals Susquehanna International Group, LLP as the second largest holder in the company with a control over 0.45% of the outstanding shares. Its stake is worth $0.28 million for having 67527.0 shares in hand.
Susquehanna Fundamental Investments, LLC also came holding a key position in the company during the recent quarter and it now holds 0.43% of the outstanding shares. With this there are now 17 institutions which have possession in GENE’s shares.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Genetic Technologies Limited was 10.87 while posting a debt to equity ratio of 0.02. The count was 1.85 for long-term debt to equity ratio.
Genetic Technologies Limited’s return on equity, or ROE, is -78.90%, compared to the industry average of 0.81% for Healthcare – Diagnostics & Research. Although this indicates that GENE fails to use its equity well, the metric will vary significantly depending on the industry.
Technical Analysis of Genetic Technologies Limited (NASDAQ:GENE) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Genetic Technologies Limited (GENE), we notice that the stock’s 20-day average volume is at 1,176,680 shares and 50% of short term indicators are suggesting the stock as Sell. Its 50-day average volume of 1,228,900 shares. And to end, GENE’s 100-day average volume is 1,592,226 shares with 100% of the long-term indicators pointing towards Buy for the stock.